EDSA

SEC source: 0001171843-25-000868 · ownership.xml · derivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100

Underlying: Common Shares · 520,833 shares

Expires not disclosed

F3 · price: On February 11, 2025, the Reporting Person purchased in a private placement, 100 shares of the Issuer's newly designated Series B-1 Convertible Preferred Shares (the "Preferred Shares"), stated value $10,000 per share for an aggregate purchase price of $1.0 million. The Preferred Shares are immediately convertible at $1.92 per share, to the extent that after giving effect to such conversion the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer.

F1 · derivative.expiration_date: The Preferred Shares are perpetual and therefore have no expiration date.

F2 · derivative.underlying_shares: Each Preferred Share is convertible at any time, at the option of the holder, into a number of common shares determined by dividing the stated value of the Preferred Share ($10,000 per share), plus all other amounts due in respect of such Preferred Share (excluding distributions), by the conversion price at the time of conversion.

SEC source: 0001171843-25-000867 · ownership.xml · nonDerivative · entry 1

Marshall Patrick · CIK 0001978257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,666

F1 · price: On February 12, 2025, the Reporting Person purchased in a private placement, 41,666 common shares, without par value, of the Issuer, for a purchase price of $1.92 per share.

SEC source: 0001171843-25-000620 · ownership.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,408

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001171843-25-000056 · ownership.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,144

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001171843-24-006707 · ownership.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,668

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001171843-24-006302 · ownership.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,248

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001171843-24-005964 · ownership.xml · derivative · entry 2

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation

Disclosed balance after: 326,560

Underlying: Common Stock · 326,560 shares

Expires 2029-10-30

F3 · price: On October 30, 2024, the Reporting Person purchased in a private placement, (i) 150 shares of the Issuer's newly designated Series A-1 Convertible Preferred Shares (the "Preferred Shares"), stated value $10,000 per share and (ii) warrants (the "Warrants") to purchase up to an aggregate of 326,560 common shares. The Preferred Shares are immediately convertible, and the Warrants are immediately exercisable, at $3.445 per share, in each case, to the extent that after giving effect to such conversion and/or exercise the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of common shares equal to 75% of the common shares underlying the Preferred Share at a combined purchase price of $10,272.13.

F4 · ownership.nature: Pardeep Medicine Professional Corporation is wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001171843-24-005964 · ownership.xml · derivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation

Disclosed balance after: 150

Underlying: Common Stock · 435,414 shares

Expires not disclosed

F3 · price: On October 30, 2024, the Reporting Person purchased in a private placement, (i) 150 shares of the Issuer's newly designated Series A-1 Convertible Preferred Shares (the "Preferred Shares"), stated value $10,000 per share and (ii) warrants (the "Warrants") to purchase up to an aggregate of 326,560 common shares. The Preferred Shares are immediately convertible, and the Warrants are immediately exercisable, at $3.445 per share, in each case, to the extent that after giving effect to such conversion and/or exercise the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of common shares equal to 75% of the common shares underlying the Preferred Share at a combined purchase price of $10,272.13.

F1 · derivative.expiration_date: The Preferred Shares are perpetual and therefore have no expiration date.

F2 · derivative.underlying_shares: Each Preferred Share is convertible at any time, at the option of the holder, into a number of common shares determined by dividing the stated value of the Preferred Share ($10,000 per share), plus any accrued and unpaid dividends, by the conversion price at the time of conversion. Until the three-year anniversary of the day of issuance, holders of Preferred Shares are entitled to an annual return equal to 10% of the stated value per Preferred Share payable by the issuance of common shares at the conversion price upon a buy-back by the Issuer, liquidation or on conversion at the conversion price (calculated daily).

F4 · ownership.nature: Pardeep Medicine Professional Corporation is wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001171843-24-005464 · ownership.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,618

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001171843-24-005045 · ownership.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,318

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001171843-24-004413 · ownership.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,263

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001654954-24-008617 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,946

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001654954-24-007354 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,931

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001654954-24-005413 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,146

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001654954-24-004189 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,063

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001654954-24-003606 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

Pardeep Nijhawan Medicine Professional Corp · CIK 0001780021 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation

Disclosed balance after: 341,702

F1 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001654954-24-002509 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,810

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001654954-24-001264 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,045

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

SEC source: 0001654954-24-000528 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,067

F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

F2 · balance_after: Shares reported reflect a 1-for-7 reverse share split effective October 11, 2023.

SEC source: 0001654954-23-010168 · section16.xml · nonDerivative · entry 1

Lemieux Stephen · CIK 0001983036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,400

F1 · price: Reflects a grant of restricted share units ("RSUs"), which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. These RSUs represent awards received in lieu of certain compensation fees earned by Reporting Person. The number of RSUs was determined by dividing such fees by the 5-day volume weighted average price (VWAP) of the Issuer's common shares through July 31, 2023.

SEC source: 0001654954-23-010167 · section16.xml · nonDerivative · entry 1

Brooks Michael J · CIK 0001779126 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,680

F1 · price: Reflects a grant of restricted share units ("RSUs"), which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. These RSUs represent awards received in lieu of a portion of Reporting Person's cash bonus earned for the calendar year ending December 31, 2022. The number of RSUs was determined by dividing such portion of the cash bonus by the 5-day volume weighted average price (VWAP) of the Issuer's common shares through July 31, 2023.

SEC source: 0001654954-23-010166 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 694,112

F1 · price: Reflects a grant of restricted share units ("RSUs"), which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. These RSUs represent awards received in lieu of a portion of Reporting Person's cash bonus earned for the calendar year ending December 31, 2022. The number of RSUs was determined by dividing such portion of the cash bonus by the 5-day volume weighted average price (VWAP) of the Issuer's common shares through July 31, 2023.

SEC source: 0001654954-23-009531 · section16.xml · derivative · entry 1

MacDonald Sean Arthur · CIK 0001778981 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2023-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009527 · section16.xml · derivative · entry 1

Sistilli Carlo · CIK 0001777988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2023-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009535 · section16.xml · derivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Shares · 120,000 shares

Expires 2023-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the date of grant.

SEC source: 0001654954-23-009534 · section16.xml · derivative · entry 1

Lemieux Stephen · CIK 0001983036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Shares · 75,000 shares

Expires 2023-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the date of grant.

SEC source: 0001654954-23-009532 · section16.xml · derivative · entry 1

Marshall Patrick · CIK 0001978257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2023-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009533 · section16.xml · derivative · entry 1

Brooks Michael J · CIK 0001779126 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Shares · 80,000 shares

Expires 2023-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the date of grant.

SEC source: 0001654954-23-009530 · section16.xml · derivative · entry 1

Chypyha Joan · CIK 0001978315 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2023-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009529 · section16.xml · derivative · entry 1

OAKES FRANK R. · CIK 0001620188 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2023-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009528 · section16.xml · derivative · entry 1

Olson Charles V · CIK 0001663298 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2023-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009597 · section16.xml · derivative · entry 1

MacDonald Sean Arthur · CIK 0001778981 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009599 · section16.xml · derivative · entry 1

Sistilli Carlo · CIK 0001777988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009605 · section16.xml · derivative · entry 1

Olson Charles V · CIK 0001663298 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009601 · section16.xml · derivative · entry 1

Brooks Michael J · CIK 0001779126 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Shares · 80,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the date of grant.

SEC source: 0001654954-23-009600 · section16.xml · derivative · entry 1

Chypyha Joan · CIK 0001978315 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009596 · section16.xml · derivative · entry 1

Marshall Patrick · CIK 0001978257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009598 · section16.xml · derivative · entry 1

OAKES FRANK R. · CIK 0001620188 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC source: 0001654954-23-009594 · section16.xml · derivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Shares · 120,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the date of grant.

SEC source: 0001654954-23-009593 · section16.xml · derivative · entry 1

Lemieux Stephen · CIK 0001983036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Shares · 75,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the date of grant.

SEC source: 0001213900-23-002248 · ownership.xml · nonDerivative · entry 4

van der Velden Peter · CIK 0001778046 · 10% owner

Lumira Capital Investment Management Inc. · CIK 0001702636 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Lumira Capital II (International), L.P.

Disclosed balance after: 150,275

F1 · ownership.nature: This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001213900-23-002248 · ownership.xml · nonDerivative · entry 3

van der Velden Peter · CIK 0001778046 · 10% owner

Lumira Capital Investment Management Inc. · CIK 0001702636 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Lumira Capital II, L.P.

Disclosed balance after: 1,625,133

F1 · ownership.nature: This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001213900-23-002248 · ownership.xml · nonDerivative · entry 2

van der Velden Peter · CIK 0001778046 · 10% owner

Lumira Capital Investment Management Inc. · CIK 0001702636 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Lumira Capital II (International), L.P.

Disclosed balance after: 163,170

F1 · ownership.nature: This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001213900-23-002248 · ownership.xml · nonDerivative · entry 1

van der Velden Peter · CIK 0001778046 · 10% owner

Lumira Capital Investment Management Inc. · CIK 0001702636 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Lumira Capital II, L.P.

Disclosed balance after: 1,764,583

F1 · ownership.nature: This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001654954-22-014745 · section16.xml · derivative · entry 9

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

Pardeep Nijhawan Medicine Professional Corp · CIK 0001780021 · Director · Chief Executive Officer · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 114,131

Underlying: Common Share · 114,131 shares

Expires not disclosed

F4 · security: Consists of Class B Warrants to purchase Common Shares.The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date.

F1 · price: The reported securities are included within 228,262 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share.

F4 · derivative.exercise_date: Consists of Class B Warrants to purchase Common Shares.The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date.

F4 · derivative.expiration_date: Consists of Class B Warrants to purchase Common Shares.The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date.

SEC source: 0001654954-22-014745 · section16.xml · derivative · entry 8

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

Pardeep Nijhawan Medicine Professional Corp · CIK 0001780021 · Director · Chief Executive Officer · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation

Disclosed balance after: 114,131

Underlying: Common Shares · 114,131 shares

Expires not disclosed

F4 · security: Consists of Class B Warrants to purchase Common Shares.The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date.

F1 · price: The reported securities are included within 228,262 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share.

F4 · derivative.exercise_date: Consists of Class B Warrants to purchase Common Shares.The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date.

F4 · derivative.expiration_date: Consists of Class B Warrants to purchase Common Shares.The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date.

F2 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Pardeep Nijhawan.

SEC source: 0001654954-22-014745 · section16.xml · derivative · entry 7

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

Pardeep Nijhawan Medicine Professional Corp · CIK 0001780021 · Director · Chief Executive Officer · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 114,131

Underlying: Common Share · 114,131 shares

Expires not disclosed

F3 · security: Consists of Class A Warrants to purchase Common Shares.The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date.

F1 · price: The reported securities are included within 228,262 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share.

F3 · derivative.exercise_date: Consists of Class A Warrants to purchase Common Shares.The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date.

F3 · derivative.expiration_date: Consists of Class A Warrants to purchase Common Shares.The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date.

SEC source: 0001654954-22-014745 · section16.xml · derivative · entry 6

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

Pardeep Nijhawan Medicine Professional Corp · CIK 0001780021 · Director · Chief Executive Officer · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation

Disclosed balance after: 114,131

Underlying: Common Shares · 114,131 shares

Expires not disclosed

F3 · security: Consists of Class A Warrants to purchase Common Shares.The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date.

F1 · price: The reported securities are included within 228,262 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share.

F3 · derivative.exercise_date: Consists of Class A Warrants to purchase Common Shares.The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date.

F3 · derivative.expiration_date: Consists of Class A Warrants to purchase Common Shares.The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date.

F2 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Pardeep Nijhawan.

SEC source: 0001654954-22-014745 · section16.xml · nonDerivative · entry 2

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

Pardeep Nijhawan Medicine Professional Corp · CIK 0001780021 · Director · Chief Executive Officer · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 228,262

F1 · price: The reported securities are included within 228,262 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share.

SEC source: 0001654954-22-014745 · section16.xml · nonDerivative · entry 1

Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner

Pardeep Nijhawan Medicine Professional Corp · CIK 0001780021 · Director · Chief Executive Officer · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation

Disclosed balance after: 2,356,914

F1 · price: The reported securities are included within 228,262 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share.

F2 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Pardeep Nijhawan.